{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:21:06Z","timestamp":1782829266231,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-025-01476-1","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:49:35Z","timestamp":1751554175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA\u2013IL PSO (Italian Landscape Psoriasis)"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele C.","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia V.","family":"Di Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Dragotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"10281","key":"1476_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"key":"1476_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","volume":"11","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117. https:\/\/doi.org\/10.3389\/fphar.2020.00117.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1476_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clindermatol.2013.11.001","volume":"32","author":"I Grozdev","year":"2014","unstructured":"Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32(3):343\u201350. https:\/\/doi.org\/10.1016\/j.clindermatol.2013.11.001.","journal-title":"Clin Dermatol"},{"issue":"4","key":"1476_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138. https:\/\/doi.org\/10.1111\/bjd.18245.","journal-title":"Br J Dermatol"},{"key":"1476_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2024.12.017","author":"M Almenara-Blasco","year":"2025","unstructured":"Almenara-Blasco M, Carmona-P\u00edrez J, Gracia-Caza\u00f1a T, et\u00a0al. Unraveling multimorbidity patterns of psoriasis using network analysis. Actas Dermosifiliogr. 2025. https:\/\/doi.org\/10.1016\/j.ad.2024.12.017.","journal-title":"Actas Dermosifiliogr"},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"740968","DOI":"10.3389\/fimmu.2021.740968","volume":"12","author":"P Liu","year":"2022","unstructured":"Liu P, Kuang Y, Ye L, et\u00a0al. Predicting the risk of psoriatic arthritis in plaque psoriasis patients: development and assessment of a new predictive nomogram. Front Immunol. 2022;12:740968. https:\/\/doi.org\/10.3389\/fimmu.2021.740968.","journal-title":"Front Immunol"},{"issue":"5","key":"1476_CR7","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901. https:\/\/doi.org\/10.3390\/ijms24054901.","journal-title":"Int J Mol Sci"},{"key":"1476_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.12.013","volume":"52","author":"P Karmacharya","year":"2022","unstructured":"Karmacharya P, Wright K, Achenbach SJ, et\u00a0al. Time to transition from psoriasis to psoriatic arthritis: a population-based study. Semin Arthritis Rheum. 2022;52: 151949. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.12.013.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1476_CR9","doi-asserted-by":"publisher","first-page":"300060523122101","DOI":"10.1177\/03000605231221014","volume":"52","author":"WY Loo","year":"2024","unstructured":"Loo WY, Tee YC, Han WH, et\u00a0al. Predictive factors of psoriatic arthritis in a diverse population with psoriasis. J Int Med Res. 2024;52(1):3000605231221014. https:\/\/doi.org\/10.1177\/03000605231221014.","journal-title":"J Int Med Res"},{"issue":"3","key":"1476_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5114\/reum.2017.68912","volume":"55","author":"P Sobolewski","year":"2017","unstructured":"Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131\u20135. https:\/\/doi.org\/10.5114\/reum.2017.68912.","journal-title":"Reumatologia"},{"issue":"3","key":"1476_CR11","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1080\/09546634.2021.1899112","volume":"33","author":"A Narcisi","year":"2022","unstructured":"Narcisi A, Valenti M, De Simone C, et\u00a0al. Effects of TNF-\u03b1 inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients. J Dermatolog Treat. 2022;33(3):1703\u20136. https:\/\/doi.org\/10.1080\/09546634.2021.1899112.","journal-title":"J Dermatolog Treat"},{"key":"1476_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","volume":"157","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et\u00a0al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157:1\u201378. https:\/\/doi.org\/10.23736\/S2784-8671.21.07132-2.","journal-title":"Ital J Dermatol Venerol"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","volume":"16","author":"M Valenti","year":"2022","unstructured":"Valenti M, Narcisi A, Pavia G, Gargiulo L, Costanzo A. What can IBD specialists learn from IL-23 trials in dermatology? J Crohns Colitis. 2022;16:ii20\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac023.","journal-title":"J Crohns Colitis"},{"key":"1476_CR14","unstructured":"European Medicines Agency. Skyrizi (risankizumab): summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi. Accessed 9 April 2025"},{"key":"1476_CR15","unstructured":"European Medicines Agency. Tremfya (guselkumab): summary of product characteristics. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya. Accessed 9 April 2025"},{"issue":"3","key":"1476_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et\u00a0al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1476_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et\u00a0al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1476_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, et\u00a0al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323. https:\/\/doi.org\/10.1111\/bjd.15750.","journal-title":"Br J Dermatol"},{"key":"1476_CR19","doi-asserted-by":"publisher","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et\u00a0al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2020;395(10230):1114. https:\/\/doi.org\/10.1016\/S0140-6736(20)30680-2.].\u00a0Lancet. 2020;395(10230):1115\u20131125. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8","DOI":"10.1016\/S0140-6736(20)30680-2"},{"key":"1476_CR20","doi-asserted-by":"publisher","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et\u00a0al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2020;395(10230):1114. https:\/\/doi.org\/10.1016\/S0140-6736(20)30741-8.].\u00a0Lancet. 2020;395(10230):1126\u20131136. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4","DOI":"10.1016\/S0140-6736(20)30741-8"},{"issue":"9","key":"1476_CR21","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/jcm13092691","volume":"13","author":"M Megna","year":"2024","unstructured":"Megna M, Ruggiero A, Martora F, Vallone Y, Guerrasio G, Potestio L. Long-term efficacy and safety of guselkumab in psoriasis patients who failed anti-IL17: a two-year real-life study. J Clin Med. 2024;13(9):2691. https:\/\/doi.org\/10.3390\/jcm13092691.","journal-title":"J Clin Med"},{"issue":"3","key":"1476_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/rheumatology\/keab509","volume":"61","author":"I Pantano","year":"2022","unstructured":"Pantano I, Mauro D, Romano F, et\u00a0al. Real-life efficacy of guselkumab in patients with early psoriatic arthritis. Rheumatology (Oxford). 2022;61(3):1217\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/keab509.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1476_CR23","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1007\/s13555-024-01270-5","volume":"14","author":"M Valenti","year":"2024","unstructured":"Valenti M, Ibba L, CascioIngurgio R, et\u00a0al. A 3-year multicentric study on switching from ustekinumab to guselkumab in partial responders with psoriasis-IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb). 2024;14(11):2987\u201397. https:\/\/doi.org\/10.1007\/s13555-024-01270-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1476_CR24","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/rheumatology\/keae220","volume":"64","author":"P Ruscitti","year":"2025","unstructured":"Ruscitti P, Pantano I, Cataldi G, et\u00a0al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort. Rheumatology (Oxford). 2025;64(3):1122\u201330. https:\/\/doi.org\/10.1093\/rheumatology\/keae220.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1476_CR25","doi-asserted-by":"publisher","first-page":"2199108","DOI":"10.1080\/09546634.2023.2199108","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Alfano A, et\u00a0al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023;34(1):2199108. https:\/\/doi.org\/10.1080\/09546634.2023.2199108.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"1476_CR26","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.3390\/jcm13092552","volume":"13","author":"M Megna","year":"2024","unstructured":"Megna M, Balato A, Caccavale S, et\u00a0al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 3-year multicenter study. J Clin Med. 2024;13(9):2552. https:\/\/doi.org\/10.3390\/jcm13092552.","journal-title":"J Clin Med"},{"issue":"10201","key":"1476_CR27","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et\u00a0al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(19)31773-8.","journal-title":"Lancet"},{"issue":"7","key":"1476_CR28","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, Mashiko S, Angsana J, et\u00a0al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707-1718.e9. https:\/\/doi.org\/10.1016\/j.jid.2021.01.005.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1476_CR29","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, et\u00a0al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016\u201327. https:\/\/doi.org\/10.1111\/jdv.19236.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1476_CR30","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/jdv.19464","volume":"38","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et\u00a0al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (Italian Landscape Psoriasis). J Eur Acad Dermatol Venereol. 2024;38(1):e113\u20136. https:\/\/doi.org\/10.1111\/jdv.19464.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1476_CR31","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, et\u00a0al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359. https:\/\/doi.org\/10.1111\/bjd.20568.","journal-title":"Br J Dermatol"},{"key":"1476_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf010","author":"L Mastorino","year":"2025","unstructured":"Mastorino L, Dapavo P, Ortoncelli M, et\u00a0al. Drug survival, effectiveness, and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years. Clin Exp Dermatol. 2025. https:\/\/doi.org\/10.1093\/ced\/llaf010.","journal-title":"Clin Exp Dermatol"},{"key":"1476_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/PTT.S372262","volume":"12","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205\u201312. https:\/\/doi.org\/10.2147\/PTT.S372262.","journal-title":"Psoriasis (Auckl)"},{"issue":"4","key":"1476_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1159\/000520290","volume":"238","author":"G Kokolakis","year":"2022","unstructured":"Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM. Brodalumab is associated with high rates of complete clearance and quality of life improvement: a subgroup analysis of patients with psoriasis and concomitant psoriatic arthritis. Dermatology. 2022;238(4):620\u20139. https:\/\/doi.org\/10.1159\/000520290.","journal-title":"Dermatology"},{"issue":"2","key":"1476_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/jcm13020495","volume":"13","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et\u00a0al. Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting: a three-year retrospective multicenter study-IL PSO (Italian Landscape Psoriasis). J Clin Med. 2024;13(2):495. https:\/\/doi.org\/10.3390\/jcm13020495.","journal-title":"J Clin Med."},{"issue":"2","key":"1476_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-023-00816-1","volume":"25","author":"L Puig","year":"2024","unstructured":"Puig L, Costanzo A, de Jong EMGJ, et\u00a0al. Guselkumab-treated patients with plaque psoriasis who achieved complete skin clearance for \u2265 156 consecutive weeks: a post-hoc analysis from the VOYAGE 1 clinical trial. Am J Clin Dermatol. 2024;25(2):315\u201325. https:\/\/doi.org\/10.1007\/s40257-023-00816-1.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1476_CR37","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s13555-024-01182-4","volume":"14","author":"M Valenti","year":"2024","unstructured":"Valenti M, Gargiulo L, Ibba L, et\u00a0al. Long-term effectiveness and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study-IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb). 2024;14(6):1649\u201357. https:\/\/doi.org\/10.1007\/s13555-024-01182-4.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1476_CR38","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, et\u00a0al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891\u2013904. https:\/\/doi.org\/10.1007\/s40257-022-00722-y.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1476_CR39","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1080\/09546634.2022.2079596","volume":"33","author":"E Del Alc\u00e1zar","year":"2022","unstructured":"Del Alc\u00e1zar E, L\u00f3pez-Ferrer A, Mart\u00ednez-Dom\u00e9nech \u00c1, et\u00a0al. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. J Dermatolog Treat. 2022;33(6):2878\u201380. https:\/\/doi.org\/10.1080\/09546634.2022.2079596.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1476_CR40","doi-asserted-by":"publisher","first-page":"2241585","DOI":"10.1080\/09546634.2023.2241585","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Vignoli CA, et\u00a0al. Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study. J Dermatolog Treat. 2023;34(1):2241585. https:\/\/doi.org\/10.1080\/09546634.2023.2241585.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01476-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01476-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01476-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:49:37Z","timestamp":1751554177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01476-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":40,"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01476-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, and Boehringer Ingelheim. Luciano Ibba has been a consultant for Almirall. Paolo Dapavo has been a speaker for Novartis, AbbVie, Sanofi, UCB, Janssen, Eli Lilly, and Leo Pharma. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma, and Almirall. Angelo V. Marzano reports consultancy\/advisory board disease-relevant honoraria from AbbVie, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi, and UCB. Francesco Loconsole served on advisory boards and\/or received honoraria for lectures from Abbvie, Janssen-Cilag, Novartis, Lilly, and Sanofi. Martina Burlando has acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, and UCB Pharma. Anna Balato has served as consultant and\/or has received fees from Abbvie, Almirall, Amgen, BI, BMS, Eli-Lilly, Janssen, Leo-Pharma, Novartis, Pfizer, Sanofi, and UCB. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, Janssen, Leo Pharma, and Novartis. Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Janssen-Cilag, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung Bioepis, and Sanofi. Emanuele Trovato is involved in an intermittent project focused on consulting and\/or advisory relationships and\/or travel-congress support with Eli Lilly, Novartis, Janssen-Cilag, AbbVie, and Almirall. Claudia Lasagni declares a conflict of interest with AbbVie, Novartis, Eli Lilly, and Almirall. Claudio Guarneri has been a scientific consultant, speaker, and clinical study investigator for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Almirall, and Leo Pharma. Simone Ribero has served as an advisory board member and\/or consultant and has received fees and speaker\u2019s honoraria or has participated in clinical studies for AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, and Sanofi Genzyme. Francesca M. Gaiani acted as a speaker or consultant for Novartis, AbbVie, Eli Lilly, Celgene, Leo Pharma, and Almirall. Carlo G. Carrera\u00a0has served as a board participant or speaker for Abbvie, Lilly, Janssen, Novartis, Celgene, Almirall, and Leopharma. Emanuele C. Cozzani acted as a speaker or consultant for Abbvie, Almirall, Eli Lilly, Leo-Pharma, and Novartis. Andrea Sechi has received honoraria from Novartis, DS Laboratories, Cantabria Labs Difa Cooper, and Eli Lilly. Rossana Moroni has been a consultant for Almirall. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and received research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Sara Di Giulio, Valentina Dini, Massimo Travaglini, Nicola Zerbinati, Eugenia V. Di Brizzi, Alessandra Michelucci, Luca Potestio, Martina Maurelli, Martina Dragotto, Luca Mastorino, Eleonora Bongiovanni, and Francesco Messina have no conflicts of interest to declare. Mario Valenti is an Editorial Board Member of Dermatology and Therapy. Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Institutional review board approval was exempted, as the study protocol did not deviate from standard clinical practice. All patients received guselkumab, as per good clinical practice, in accordance with European guidelines. All included patients had provided written consent for retrospective study of data collected during routine clinical practice (demographics and clinical scores). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}